Acute Versus Progressive Onset of Diabetes in NOD Mice: Potential Implications for Therapeutic Interventions in Type 1 Diabetes

被引:41
|
作者
Mathews, Clayton E. [1 ]
Xue, Song [1 ]
Posgai, Amanda [1 ]
Lightfoot, Yaima L. [1 ]
Li, Xia [3 ]
Lin, Andrea [1 ,2 ]
Wasserfall, Clive [1 ]
Haller, Michael J. [4 ]
Schatz, Desmond [4 ]
Atkinson, Mark A. [1 ]
机构
[1] Univ Florida, Dept Pathol, Gainesville, FL 32611 USA
[2] Cent S Univ, Natl Clin Res Ctr Metab Dis, Inst Metab & Endocrinol, Xiangya Hosp 2, Changsha, Hunan, Peoples R China
[3] Cent S Univ, Natl Clin Res Ctr Metab Dis, Metab Syndrome Res Ctr, Key Lab Diabet Immunol,Minist Educ,Diabet Ctr, Changsha, Hunan, Peoples R China
[4] Univ Florida, Dept Pediat, Gainesville, FL USA
基金
美国国家卫生研究院;
关键词
ANTI-CD3; MONOCLONAL-ANTIBODY; BETA-CELL MASS; INSULIN-SECRETION; MELLITUS; DISEASE; MOUSE; HETEROGENEITY; GLUCOSE;
D O I
10.2337/db15-0449
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Most natural history models for type 1 diabetes (T1D) propose that overt hyperglycemia results after a progressive loss of insulin-secreting beta-cell mass and/or function. To experimentally address this concept, we prospectively determined morning blood glucose measurements every other day in multiple cohorts (total n = 660) of female NOD/ShiLtJ mice starting at 8 weeks of age until diabetes onset or 26 weeks of age. Consistent with this notion, a majority of mice that developed diabetes (354 of 489 [72%]) displayed a progressive increase in blood glucose with transient excursions >200 mg/dL, followed by acute and persistent hyperglycemia at diabetes onset. However, 135 of the 489 (28%) diabetic animals demonstrated normal glucose values followed by acute (i.e., sudden) hyperglycemia. Interestingly, diabetes onset occurred earlier in mice with acute versus progressive disease onset (15.37 +/- 0.3207 vs. 17.44 +/- 0.2073 weeks of age, P < 0.0001). Moreover, the pattern of onset (i.e., progressive vs. acute) dramatically influenced the ability to achieve reversal of T1D by immunotherapeutic intervention, with increased effectiveness observed in situations of a progressive deterioration in euglycemia. These studies highlight a novel natural history aspect in this animal model, one that may provide important guidance for the selection of subjects participating in human trials seeking disease reversal.
引用
收藏
页码:3885 / 3890
页数:6
相关论文
共 50 条
  • [41] Comparative Pathogenesis of Autoimmune Diabetes in Humans, NOD Mice, and Canines: Has a Valuable Animal Model of Type 1 Diabetes Been Overlooked?
    O'Kell, Allison L.
    Wasserfall, Clive
    Catchpole, Brian
    Davison, Lucy J.
    Hess, Rebecka S.
    Kushner, Jake A.
    Atkinson, Mark A.
    DIABETES, 2017, 66 (06) : 1443 - 1452
  • [42] Genetic Restoration of Heme Oxygenase-1 Expression Protects from Type 1 Diabetes in NOD Mice
    Pogu, Julien
    Tzima, Sotiria
    Kollias, Georges
    Anegon, Ignacio
    Blancou, Philippe
    Simon, Thomas
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (07):
  • [43] Oral gavage delivery of Cornus officinalis extract delays type 1 diabetes onset and hyperglycemia in non-obese diabetic (NOD) mice
    Fletcher, Justin D.
    Olsson, Grace E.
    Zhang, Y. Clare
    Burkhardt, Brant R.
    FEBS OPEN BIO, 2024, 14 (03): : 434 - 443
  • [44] Maternal Diabetes in Youth-Onset Type 2 Diabetes Is Associated With Progressive Dysglycemia and Risk of Complications
    Shah, Rachana D.
    Chernausek, Steven D.
    El Ghormli, Laure
    Geffner, Mitchell E.
    Keady, Joyce
    Kelsey, Megan M.
    Farrell, Ryan
    Tesfaldet, Bereket
    Tryggestad, Jeanie B.
    Van Name, Michelle
    Isganaitis, Elvira
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (05) : 1120 - 1131
  • [45] Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes
    Hagopian, William
    Ferry, Robert J., Jr.
    Sherry, Nicole
    Carlin, David
    Bonvini, Ezio
    Johnson, Syd
    Stein, Kathryn E.
    Koenig, Scott
    Daifotis, Anastasia G.
    Herold, Kevan C.
    Ludvigsson, Johnny
    DIABETES, 2013, 62 (11) : 3901 - 3908
  • [46] Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus
    Guglielmi, Chiara
    Williams, Stefan Rhys
    Del Toro, Rossella
    Pozzilli, Paolo
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (06) : 841 - 846
  • [47] Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
    Avgerinos, Ioannis
    Liakos, Aris
    Tsapas, Apostolos
    Bekiari, Eleni
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 : 2549 - 2557
  • [48] TRPV1: A Potential Therapeutic Target in Type 2 Diabetes and Comorbidities?
    Gram, Dorte X.
    Holst, Jens J.
    Szallasi, Arpad
    TRENDS IN MOLECULAR MEDICINE, 2017, 23 (11) : 1002 - 1013
  • [49] Pioglitazone Might Prevent the Progression of Slowly Progressive Type 1 Diabetes
    Kawano, Yoshinaga
    Irie, Junichiro
    Nakatani, Hiroshi
    Yamada, Satoru
    INTERNAL MEDICINE, 2009, 48 (12) : 1037 - 1039
  • [50] Aberrant ROCK activation promotes the development of type I diabetes in NOD mice
    Biswas, Partha S.
    Gupta, Sanjay
    Chang, Emily
    Bhagat, Govind
    Pernis, Alessandra B.
    CELLULAR IMMUNOLOGY, 2011, 266 (02) : 111 - 115